App-Quantinova.ai

EXPRESSION QUANTITATIVE TRAIT LOCI IN EARLY TREATMENT-NAÏVE RHEUMATOID ARTHRITIS

K. Goldmann - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

FACTOR ANALYSIS OF FRAGILITY FRACTURES BY SITE IN PATIENTS REFERRED FOR DUAL-ENERGY X-RAY ABSORPTIOMETRY SCAN

Z. Sultan - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

FACTORS ASSOCIATED WITH LONGITUDINAL BONE MINERAL DENSITY CHANGES IN RHEUMATOID ARTHRITIS

R. Ark - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Glucocorticoid

FACTORS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHY: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRY

S. A. Yeoh - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Inclusion body myositis

N/A

FACTORS TO CONSIDER FOR MEASURING THE EFFECT OF LUNG FUNCTION ON PATIENT REPORTED OUTCOMES IN SYSTEMIC SCLEROSIS PATIENTS: ANALYSIS OF THE EUSTAR DATABASE.

M. G. Lazzaroni - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Pulmonary arterial hypertension

N/A

FATAL BUT PREVENTABLE - SINGLE CENTRE SERIES OF 6 CASES OF PNEUMOCYSTIS JIROVECII PNEUMONIA (PJP) IN PATIENTS WITH AUTO-IMMUNE INFLAMMATORY RHEUMATIC DISEASE (AIIRD) IN ONE YEAR.

A. Escudero Siosi - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Pneumocystis Jiroveci Pneumonia

N/A

FIBROBLAST/MACROPHAGE CROSSTALK VIA LACTATE: NEW THERAPEUTIC TARGET IN RHEUMATOID ARTHRITIS

V. Pucino - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

FIRST INTERIM ANALYSIS OF THE INTERNATIONAL X-LINKED HYPOPHOSPHATAEMIA (XLH) REGISTRY: ADULT POPULATION BASELINE CHARACTERISTICS

K. Briot - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

X-linked hypophosphataemia

N/A

FLARES OF RHEUMATOID ARTHRITIS FOLLOWING CORONAVIRUS VACCINATION

R. Hayward - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

FREQUENCY OF VISUAL MANIFESTATIONS IN GIANT CELL ARTERITIS IN NORFOLK

S. Mansfield-Smith - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Giant cell arteritis

N/A

FUNCTIONAL GENOMICS IN PRIMARY T CELLS AND MONOCYTES IDENTIFIES MECHANISMS BY WHICH GENETIC SUSCEPTIBILITY LOCI INFLUENCE SYSTEMIC SCLEROSIS RISK

D. Gonzalez Serna - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

FUNCTIONAL GENOMICS INVESTIGATION OF THE ANKYLOSING SPONDYLITIS ASSOCIATED LOCUS RUNX3

C. Cohen - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

N/A

GENE REGULATION IN T-CELLS FROM PsA PATIENTS DIFFERS BETWEEN PERIPHERAL BLOOD AND THE INFLAMED JOINTS: IMPLICATIONS FOR THE INTERPRETATION OF GWAS SIGNALS

C. Shi - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

GENETIC ANALYSIS OF WHOLE EXOME SEQUENCING IN A COHORT OF CHILDREN WITH REFRACTORY JIA REVEALS GENETIC RISK FACTORS FOR RARE JUVENILE DISEASES.

M. Tordoff - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

GENETIC INVESTIGATION OF TUMOUR NECROSIS FACTOR INHIBITOR IMMUNOGENICITY IN PATIENTS WITH RHEUMATOID ARTHRITIS

C. F. Yap - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

GIANT CELL ARTERITIS-RELATED STROKE IN A MAN WITH ELDERLY-ONSET RHEUMATOID ARTHRITIS

M. Hng - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Giant cell arteritis

N/A

GLOBAL STEROID METABOLISM IN MACROPHAGES: SHAPING INFLAMMATORY FUNCTION AND DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS

C. S. Martin - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Interferon Gamma

GUSELKUMAB EFFICACY IN PSORIATIC ARTHRITIS ASSESSED BY MULTI-DOMAIN COMPOSITE INDICES: DATA FROM THE PHASE 3B COSMOS TRIAL IN A TNFi-IR POPULATION

L. Gossec - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Psoriatic arthritis

guselkumab (IV)

GUSELKUMAB MAINTAINS RESOLUTION OF DACTYLITIS AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS THROUGH 2 YEARS FROM A PHASE 3 STUDY

P. Rahman - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

guselkumab (IV)

GUSELKUMAB PROVIDES CONSISTENT AND DURABLE PAIN IMPROVEMENT IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS OF 2 PHASE 3, RANDOMIZED, CONTROLLED CLINICAL TRIALS

P. Nash - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Psoriatic arthritis

guselkumab (IV)

Filters

45280 Abstracts